Purpose : Recent limited data have shown that lipoprotein(a) (Lp(a)) may be used as much stronger predictors in screening for high blood lipid and Lp(a) is the best single marker for the presence of cardiovascular disease. However, the therapeutic response of Lp(a) independent of the cholesterol-lowering effects of statin therapy was variable in real world,. So, we investigated the predictors of therapeutic response of Lp(a) in real world. Methods : We conducted a retrospective analysis of collected data on 391 consecutive patients (mean age 61.2years, male: 49.9%) who had been performed initial statin medication (Atorvastatin 10mg (n=227), Pitavastatin 2mg(n=87), Rosuvastatin 10mg(n=65)) between June 2009 and June 2010 at our centers. We assessed initial lipid profile and follw-up lipid profile above 6 months. The patients were divided into normal Lp(a) level group (<30mg/dl) and abnormal Lp(a) group (���30mg/dl). Lp(a) change is defined that follow-up Lp(a) level minus initial Lp(a) level. Results : Initial mean total cholesterol(TC) level was 206.65mg/dl (LDL: 135.53 mg/dl, Lp(a): 33.98 mg/dl). The mean change of TC level was -30.99 mg/dl (LDL: -30.67 mg/dl, Lp(a): 1.19). Lp(a) change of abnormal Lp(a) group was more better than normal Lp(a) group (P=0.000). Also, this therapeutic response was revealed on each statin (Atorvastatin; P=0.002, Pitavastatin; P=0.010, Rosuvastatin; P=0.033). Conclusions : Initial plasma level of Lp (a) can be predict the therapeutic response of statin medication in real world. But, for more reliable result more larger study and randomized control study were required.